All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2022-09-21T08:18:41.000Z

Visual abstract | Key updates to the classification of MPN in the 5th WHO Classification of Haematolymphoid Tumours

Sep 21, 2022
Share:
Learning objective: After reading this article, learners will be able to recall key changes in the classification of myeloproliferative neoplasms and mastocytosis from the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours.

Bookmark this article

The MPN Hub is pleased to present a visual abstract highlighting key updates and changes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Updates are focused on the changes in the rationale behind the classification of myeloproliferative neoplasms and mastocytosis, focusing on combined morphologic, immunophenotypic, molecular, and cytogenetic data that help to refine diagnostic criteria and emphasize therapeutically and/or prognostically actionable biomarkers.


 

Visual Abstract

To download this visual abstract, click below.

Download here

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox